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The incorporation of fluorine atoms into functional molecules
is of wide interest in synthetic organic chemistry as well as
cognate disciplines. In particular, in medicinal chemistry, there
is a strong desire to positively influence the physicochemical
molecular properties of drug compounds by introducing fluo-
rine into biologically active molecules. Here, we present target-
ed fluoro positioning as the key design principle of converting
a weak matrix metalloproteinase-13 (MMP-13) inhibitor into
a very potent (IC50=6 nm) and highly selective (selectivity fac-
tors of >1000 over MMP-1, 2, 3, 7, 8, 9, 10, 12, 14) inhibitor
with excellent plasma and microsomal stability, and no binding
to the hERG channel (hERG: human ether-a-go-go related
gene).
Fluorine-containing compounds have gained emerging interest
in chemistry, as synthetic strategies have evolved to allow the
diverse use of this formerly exotic element.[1–6] Owing to its
small size, with a van der Waals radius of 1.47 a (in comparison
to 1.20 a for hydrogen and 1.52 a for oxygen), and its high
electronegativity (3.98 according to the Pauling scale in con-
trast to 2.20 for hydrogen), fluorine can be incorporated into
molecules to substitute a hydrogen atom and to alter the
physicochemical properties without applying major changes to
the size of the compound.[7, 8] The introduction of fluorine
atoms to drug molecules can modulate a broad range of drug
properties. Amongst others, it is reported to have an effect on
the pharmacokinetic profile, membrane permeability, and the
conformation of a molecule.[9–12] Deployment of fluorine in
identified enzyme inhibitors is of great significance in the de-
velopment process from initial hits to lead compounds when
attention is paid to preclinical properties.[13–16]
Matrix metalloproteinase-13 (MMP-13) is, within its super-
family of zinc-dependent endopeptidases, the most efficient
member with respect to the degeneration of type II collagen
and is, therefore, an established target for the treatment of dis-
eases in which tissue remodeling is out of balance, such as in
osteoarthritis and a variety of cancers.[17–21] Early inhibitors of
the target class incorporated strong metal chelators such as
hydroxamic acids. These broad-band inhibitors were highly
potent, but did not display satisfying selectivity, whereby clini-
cal trials failed because of joint-stiffening and painful side ef-
fects like musculoskeletal syndrome (MSS).[22,23] Later develop-
ments led to allosteric binders, occupying the selectivity loop
within the S1’ pocket, sparing the interaction to the zinc
ion.[24–26] Equipping selective allosteric inhibitors with weaker
metal-chelating groups, such as carboxylic acid for example,
can improve the potency of the inhibitors while maintaining
the selectivity profile.[27–29]
We selected MMP-13 as the target protein for our structure-
based drug design, employing water-mediated interactions by
targeted fluoro positioning for the optimization of potency, se-
lectivity, and preclinical ADME properties. Recently, we identi-
fied phthalimide derivative 1 (Figure 1) as a weak allosteric
inhibitor of MMP-13, displaying an IC50 value of 9.8 mm and
a rather poor stability profile in liver microsomes and
plasma.[30]
Starting with the initial weak inhibitor 1, we applied struc-
ture-based design to attach a zinc-binding moiety to the
phthalimide scaffold to gain a higher binding affinity. Accord-
ing to our modeling studies, derivatives of 1 modified by the
attachment of carboxylic acids through growing methylene
linkers can bind to the allosteric binding site as well as to the
catalytic zinc ion (Figure 2).[28]
We found that the para-substituted derivatives with chain
lengths between 2 and 5 carbon atoms are reasonable for the
elevation of inhibitor potency. Previous work indicated that
a chain length of 4 carbon atoms between the phenolic
oxygen and the zinc-recognizing carboxylic acid is the most
promising member within this set of compounds.[27] Subse-
Figure 1. Previously identified weak MMP-13 inhibitor 1 displaying poor sta-
bility in plasma and liver microsomes.
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quently, we investigated the possibility to probe water-mediat-
ed interactions through targeted fluoro positioning in the S1’
pocket (Figure 3). Although the meta position as well as the
para position indicated water-mediated interactions by the
fluoro atom within comparable distances (2.5 a for meta sub-
stitution and 2.7 a for para substitution), no possible interac-
tion for ortho substitution could be detected (Figure 3 and the
Supporting Information).
As displayed in Figure 3, owing to the small van der Waals
radius of fluorine, we could omit sterically demanding altera-
tions in this region of the receptor. This is beneficial because
of the rather limited space in the S1’ pocket. The para-fluorinat-
ed compound was of highest interest to us, as it does not dis-
play a hydrogen atom in the para position, which is prone to
metabolic degradation by cytochrome P450 enzymes.[31–34]
Driven by the promising results derived from the molecular
design approach, we synthesized compounds 2a–g (Figure 4)
in order to test our hypotheses with biological inhibitory data
(Table 1). The synthetic route and all experimental details are
given in the Supporting Information.
All synthesized compounds exhibited a higher potency com-
pared to inhibitor 1. Carboxylic acid 2c showed the lowest IC50
value of the non-fluorinated compounds (35 nm), validating
our structure-based design with a chain length of 4 carbon
atoms for the optimal linker.
Equipping this molecule with a fluorine atom in the para po-
sition resulted in compound 2d, which displayed the highest
affinity (IC50=6 nm) of all tested molecules with a very high
ligand efficiency and lipophilic ligand efficiency. An alteration
of the fluorine atom to the meta position was tolerated with
Figure 3. Targeted fluoro positioning to probe water-mediated interactions.
Table 1. MMP-13 inhibitory data for compounds 1 and 2a–g.
Inhibitor R1 R2 IC50 [nm] clogP LE
[a] LLE[b]
1 H H 9800:3400 3.94 0.25 1.07
2a H O(CH2)2COOH 2244:200 3.21 0.23 2.44
2b H O(CH2)3COOH 556:125 3.56 0.25 2.69
2c H O(CH2)4COOH 35:0.6 4.00 0.29 3.46
2d 4-F O(CH2)4COOH 6:2.5 4.15 0.31 4.07
2e 3-F O(CH2)4COOH 10:1.6 4.15 0.30 3.85
2 f 2-F O(CH2)4COOH 134:39 4.15 0.26 2.72
2g H O(CH2)5COOH 151:31 4.45 0.26 2.37
[a] The ligand efficiency (LE) was calculated as 1.4(@logIC50)/N, where N
equals the number of non-hydrogen atoms. [b] The lipophilic ligand effi-
ciency (LLE) was calculated as (@logIC50)@clogP.
Figure 2. Molecular modeling of inhibitor 1 and its elongated derivatives in
PDB 2OW9:[25] pharmacophore displayed in cyan spheres; different lengths
of methylene linkers depicted in blue [CH2] , yellow [(CH2)2] , cyan [(CH2)3] ,
green [(CH2)4] , magenta [(CH2)5] .
Figure 4. Synthesized fluoro probes 2d–f for the targeted inhibition of
MMP-13 and non-fluorinated compounds 2a–c and 2g.
ChemistryOpen 2017, 6, 192 – 195 www.chemistryopen.org T 2017 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim193
comparable potency (IC50=10 nm) in accordance with our con-
cept of targeting water-mediated interactions by the fluoro
probe (Figure 3). The boost in potency from 2c to 2d and 2e
corresponds well with our hypothesis that directed fluorine in-
corporation in this region of the ligand will have a beneficial
influence on the binding interaction between the enzyme and
its inhibitor. The almost six-fold improvement in potency from
2c to 2d is in line with literature data for this type of interac-
tion and supports our design strategy.[35,36]
For the two most potent fluorinated compounds, 2d and
2e, a selectivity profile was generated that compared the in-
hibition of MMP-13 with other members of this challenging
target family. The fluorinated compounds showed outstanding
selectivity factors of >1000 against MMP-1, 2, 3, 7, 8, 9, 10, 12,
and 14. For the most potent inhibitor 2d, as well as for the ini-
tial weak inhibitor 1, in vitro ADME properties were deter-
mined. Shake-flask solubility at pH 7.4, mouse plasma and
mouse microsomal stability, and hERG binding were measured
(hERG: human ether-a-go-go related gene). Fluorinated inhibi-
tor 2d showed consistently superior characteristics compared
to the initial inhibitor 1. The microsomal stability improved
dramatically from a half-life T1/2=30 min and an intrinsic clear-
ance Clint=55 mLmin
@1mg@1 (1) to T1/2>240 min and Clint<
10 mLmin@1mg@1 (2d). In addition, the plasma stability could
be enhanced from T1/2=181 min (1) to >240 min (2d) and the
solubility in phosphate-buffered saline pH 7.4 improved from
58:3 mm (1) to 94:2 mm (2d). Measurements of hERG inhibi-
tion of the novel inhibitor 2d revealed no hERG-related liability
for drug toxicity. The excellent pharmacokinetic profile in com-
bination with the high potency and outstanding selectivity
data qualify inhibitor 2d for further studies in relevant disease
models.
In conclusion, this study shows how probing the selectivity
loop of MMP-13 with targeted fluoro positioning enhances the
ligands potency and selectivity as well as its ADME properties.
This approach can also be adopted for other target proteins.
By using structure-based design to target the catalytic zinc ion
by a carboxylic acid and water-mediated interactions through
directed fluoro positioning in the selectivity loop, we could de-
velop an initially weak inhibitor with a rather poor pharmacoki-
netic profile into a potent and highly selective inhibitor of
MMP-13 with very high murine plasma and microsomal stabili-
ty. Suitable solubility and the absence of hERG liability make
this inhibitor a valuable candidate for studies in in vivo disease
models for cancer, arthritis, or other indications where the se-
lective inhibition of MMP-13 is of interest.
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